Plaque Psoriasis

The data presented at the EADV Congress in Madrid builds on the findings reported at 52 and 64 weeks in the phase 3 reSURFACE 1 and 2 trials.

New 12-week findings from a head-to-head phase 4 trial showed the Eli Lilly product's benefit for plaque psoriasis clearance.

How has testing and diagnosis changed?

FDA announced approval of Sorilux Foam, which had previous approval for adults, for adolescents between the ages of 12 and 17.

The lotion, Duobrii, combines halobetasol propionate, a topical steroid, with tazarotene, a retinoid, to provide 2 mechanisms of action for treating plaque psoriasis.